Novartis initiates €2.7B tender offer for MorphoSys, a German cancer drug developer, at €68/share.
Novartis has commenced a tender offer for MorphoSys, a German cancer drug developer, offering €68.00 per share in cash. The total equity value of the deal is €2.7 billion. MorphoSys' management and supervisory boards recommend shareholders accept the offer. The tender offer period will end on May 13, 2024, at 24:00 hours CEST. The deal is expected to further Novartis' commercial and development opportunities in the oncology sector.
April 11, 2024
13 Articles